On September 8 and 9, 2017, the American Society of Hematology (ASH) will hold the Meeting on Hematologic Malignancies (MHM) in Chicago. ASH has invited state hematology-oncology societies to serve as an official partner for the meeting. FLASCO has agreed to serve as a partner on this event.
About MHM
As the treatment regimens in the hematologic malignancies continue to evolve at a rapid pace, it is vital for practitioners to hear from experts about “How I Treat” these diseases. Building on the foundation of ASH’s previous State of the Art Symposia, and the success of the MHM program thus far, this year’s agenda is targeted at the learning gap between current practice and new approaches. Noted experts in the field will discuss how they treat leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms by blending available evidence and guidelines with judgment and experience. The list of confirmed speakers and program topics can be found on the ASH website at www.hematology.org/malignancies.
